R
Ruth Motter
Researcher at Élan
Publications - 33
Citations - 11776
Ruth Motter is an academic researcher from Élan. The author has contributed to research in topics: Alzheimer's disease & Amyloid precursor protein. The author has an hindex of 23, co-authored 32 publications receiving 11450 citations. Previous affiliations of Ruth Motter include Pharmacia & Sunesis Pharmaceuticals.
Papers
More filters
Journal ArticleDOI
Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse.
Dale Schenk,Robin Barbour,Whitney Dunn,Grace Gordon,Henry Grajeda,Teresa Guido,Kang Hu,Jiping Huang,Kelly Johnson-Wood,Karen Khan,Dora Kholodenko,Michael K. Lee,Zhenmei Liao,Ivan Lieberburg,Ruth Motter,Linda Mutter,Ferdie Soriano,George Shopp,Vasquez Nicki J,Christopher Vandevert,Shannan Walker,Mark Wogulis,Ted Yednock,Dora Games,Peter Seubert +24 more
TL;DR: It is reported that immunization of the young animals essentially prevented the development of β-amyloid-plaque formation, neuritic dystrophy and astrogliosis, and treatment of the older animals markedly reduced the extent and progression of these AD-like neuropathologies.
Journal ArticleDOI
Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease.
Frederique Bard,Catherine Cannon,Robin Barbour,Rae Lyn Burke,Dora Games,Henry Grajeda,Teresa Guido,Kang Hu,Jiping Huang,Kelly Johnson-Wood,Karen Khan,Dora Kholodenko,Michael K. Lee,Ivan Lieberburg,Ruth Motter,Minh Nguyen,Ferdie Soriano,Vasquez Nicki J,Kim Weiss,Brent Welch,Peter Seubert,Dale Schenk,Ted Yednock +22 more
TL;DR: Results indicate that antibodies can cross the blood–brain barrier to act directly in the central nervous system and should be considered as a therapeutic approach for the treatment of Alzheimer disease and other neurological disorders.
Journal ArticleDOI
Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice
Martin Citron,David Westaway,Weiming Xia,George A. Carlson,Thekla S. Diehl,G. Levesque,Kelly Johnson-Wood,Michael K. Lee,Peter Seubert,Angela Davis,Dora Kholodenko,Ruth Motter,R. Sherrington,Billie J. Perry,Hong Yao,Robert Strome,Ivan Lieberburg,Johanna M. Rommens,Soyeon Kim,Dale Schenk,Paul E. Fraser,Peter St. George Hyslop,Dennis J. Selkoe +22 more
TL;DR: The data demonstrate that the preseniiin mutations cause a dominant gain of function and may induce AD by enhancing Aβ42 production, thus promoting cerebral β-amyloidosis.
Journal ArticleDOI
BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics.
Steven L. Roberds,John P. Anderson,Guriqbal Basi,Michael Jerome Bienkowski,Daniel G. Branstetter,Karen S. Chen,Stephen B. Freedman,Normand Frigon,Dora Kate Games,Kang Hu,Kelly Johnson-Wood,Karl Kappenman,Thomas T. Kawabe,Ismail Kola,Ralf Kuehn,Mike Lee,Weiqun Liu,Ruth Motter,Nanette F. Nichols,Michael Power,David W. Robertson,Dale Schenk,Michael Schoor,George Shopp,Mary E. Shuck,Sukanto Sinha,Kjell A. Svensson,Gwen Tatsuno,Hartmut Tintrup,John A. Wijsman,Sarah Wright,Lisa McConlogue +31 more
TL;DR: The findings that BACE is the primary beta- secretase activity in brain and that loss of beta-secretase activity produces no profound phenotypic defects with a concomitant reduction in beta-amyloid peptide clearly indicate that Bace is an excellent therapeutic target for treatment of AD.
Journal Article
Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain
H. F. Dovey,V. John,Chen Jin Ling,P. D. S. int Andrieu,L. Y. Fang,S. B. Freedman,B. Folmer,Erich Goldbach,E. J. Holsztynska,Kun Hu,K. L. Johnson Wood,S. L. Kennedy,Dora Kholodenko,J. E. Knops,L. H. Latimer,Michael K. Lee,Z. Liao,I. M. Lieberburg,Ruth Motter,L. C. Mutter,J. Nietz +20 more